A Natural Approach to Erectile Dysfunction thatImproves Vascular Health

 

By Robert Haas, MS
A Natural Approach to Erectile Dysfunction that Improves Vascular Health

Aging individuals become very enthusiastic when they discover something that produces an immediate result.

Life Extension® members often send us samples of dietary supplements they claim have enhanced their sexual performance. These members are elated that a purported “natural” product produces such striking erection-inducing benefits and want us to inform other members.

When we try these products, we find most of them do indeed work! After we assay these products, we disappointingly find out why they are so effective.

It turns out that unscrupulous supplement makers are spiking herbal preparations with prescription drug ingredients found in Viagra®, Levitra®, or Cialis®.

So when we started getting calls about another “natural” male sex product, we were skeptical. We were impressed that five different clinical studies documented the efficacy of the nutrient combination, but we wondered, is this just another drug-spiked product pretending to be a dietary supplement?

As expected, we observed the same remarkable benefits reported in the clinical studies. What amazed us, however, was that our assays did not detect any prescription drug residue in this supplement.

Based on its underlying mechanisms of action—backed by solid scientific data—it would appear that this nutrient combination not only produces a rapid improvement in male sexual function, but may also confer significant benefit to the vascular system as well.

Erectile dysfunction is often associated with coronary artery disease.1

A nutrient formula that improves male erectile capability may very well protect against heart attack and stroke as well. This article describes the science behind this drug-free male sex enhancer.

Erectile Dysfunction Associated with Vascular Disease

Mainstream doctors generally resort to one of three FDA-approved prescription drugs (Viagra®, Cialis®, or Levitra®) to treat patients suffering from mild erectile dysfunction (ED)—with mixed results. As Mayo Clinic professor of urology Dr. Ajay Nehra recently told the New York Times, “the medications do not work for about half of the men with ED.”2

Although these drugs may help some men with ED to achieve temporary erections sufficient for sexual activity, they donothing to treat chronic endothelial dysfunction, one of ED’s stealth causes.

The unfortunate reality is that many aging men remain unaware of the link between ED and vascular disease. They go to their doctors seeking help for sexual dysfunction, get a prescription­, and leave with no idea of the creeping health dangers that may lie in store for them.

These dangers are real. “Erectile problems may show up about three years before a cardiovascular event such as a heart attack or stroke,” Dr. Ira Sharlip reported in the same New York Times article.2

Prescription drugs for ED can cost as much as $15 per pill.2 They are often accompanied by an array of side effects ranging from indigestion,3 flushing,4 blurred vision,5-7 hearing loss,8,9 congestion,10 and headache11 to more serious health problems, from neurologic disorders12 to heart attacks.3,13

These drugs provide short-term relief to ED sufferers by relaxing the smooth muscles that line the arteries, thus increasing blood flow into arteries that supply the penis. In those instances when ED is the result of plaque buildup in penile arteries, these drugs offer no long-term benefit.

For men interested in achieving optimal health—including dynamic sexual health—a better option is now available.

A Unique Strategy to Support Endothelial Health—and Restore Potency

Researchers have developed a unique natural strategy for management of erectile dysfunction that includes a blend ofPycnogenol® (French maritime pine bark extract) and L-arginine aspartate, an amino acid chelate; combined withicariin, a flavonoid compound used in Chinese herbal medicine.

A Unique Strategy to Support Endothelial Health—and Restore Potency

The interaction of these three ingredients creates a unique strategy that promises to tackle erectile dysfunction from multiple angles.

The nutrients’ underlying mechanisms of action are innovative yet elegantly simple. Here’s how it works: to get an erection, you need adequate blood flow. This requires the relaxation of the smooth muscle in the arteries of the penis. The chemical compoundnitric oxide triggers this process of relaxation, increasing the blood flow to the penis required for an erection.

Endothelial cells are responsible for nitric oxide production. They release nitric oxide synthase, an enzyme that catalyzes the production of nitric oxide from L-arginine. This process is essential to maintaining an erection. Dysfunctional endothelial cells, disabled by plaque buildup, can no longer produce enough of this enzyme.30

Pycnogenol® stimulates endothelial nitric oxide synthase to produce nitric oxide in the artery linings from the amino acid L-arginine, yielding sufficient bioactive nitric oxide to maintain an erection.31 At the same time, icariin acts toblock the enzyme responsible for causing erections to subside, known as phosphodiesterase-5 (PDE5).32

Interestingly, these nutrients not only promote erections, but also enhance male fertility and endo-thelial health. In other words, numerous distinct modes of action work together to produce a broad array of clinically proven health benefits. Meanwhile, prescription erectile dysfunction drugs such as

Viagra® support penile erection primarily by blocking the action of PDE5, without delivering any other benefit.

Pycnogenol® and L-arginine Aspartate: A Clinically Proven, Long-Term Alternative to ED Drugs

The efficacy of Pycnogenol® and L-arginine aspartate has been tested in five independent clinical studies. All of these studies showed that male sexual function was restored during supplementation with these ingredients.33-37Patients also reported an increase in sexual dreams and fantasies and more frequent morning erections. Their partners noted higher sexual interest and enhanced sexual performance.38

The first clinical trial to report successful treatment of erectile dysfunction with Pycnogenol® and L-arginine aspartate involved 40 men between 25 and 45 years of age suffering from mild ED. After treatment with arginyl aspartate (which provided the equivalent of 1.7 g L-arginine per day) for one month, only 2 patients (5% of all patients) experienced normal erections. During a second month of treatment, 80 mg Pycnogenol® per day was added to the arginine regimen and yielded a significant improvement, with 32 patients (80%) enjoying normal erections. A third month’s treatment with L-arginine, together with an increased amount of Pycnogenol® (120 mg per day), further increased the number of patients with restored normal erectile function. At the end of the trial, 37 patients, equivalent to 92.5% of all participants, achieved normal erectile function.35

WHAT YOU NEED TO KNOW: A NATURAL APPROACH TO ERECTILE DYSFUNCTION
  • A Natural Approach to Erectile Dysfunction

    A blend of Pycnogenol® and L-arginine aspartate, combined with icariin, work together to restore healthy endothelial function and promote optimal sexual performance.

  • This nutrient combination promotes healthy erections without the adverse side effects associated with drugs prescribed to treat erectile dysfunction.
  • Prescription drugs can temporarily restore erectile function for some individuals, but they do not treat chronic endothelial dysfunction, an underlying cause of heart disease, peripheral artery disease, diabetes, and erectile dysfunction.
  • Five clinical studies have found that Pycnogenol® and L-arginine aspartate work together to restore sexual function, enable erections, boost libido, performance, and sperm motility, viability, and quantity.
  • Pycnogenol®, L-arginine aspartate, and icariin promote the synthesis of nitric oxide, which is essential for healthy vascular function, providing body-wide benefits.
  • Icariin herbal extract act as a PDE5-inhibitor, the same mode of action as Viagra®, Cialis®, and Levitra®. Icariin has been shown to enhance the production of nitric oxide in human endothelial cell culture and in animal models, and exhibits testosterone-like activity.

A second clinical study examined 50 middle-aged men with low testosterone levels who suffered from ED as well as from poor fertility due to impaired sperm motility and morphology.36 Men were given 3 g L-arginine aspartate and 120 mg Pycnogenol® plus 120 mg testosterone undecanoate over a period of 11 months. A statistically significant 76% of men achieved normal sexual function and this effect was sustained during the entire treatment period. The researchers found that this treatment improved sperm quality and quantity at the end of the 1-year treatment and an astounding 40% (20 of 50 patients) achieved fertilization.

A third study—this one a randomized, double-blind, placebo-controlled, crossover study—evaluated the effects of Pycnogenol® and L-arginine aspartate on spermatozoa parameters in 50 middle-aged men diagnosed with infertility.37Investigators found improvement of sperm quality in all participants, with better results in younger men. Study results confirmed that this treatment improved sperm parameters in men with infertility.

A fourth clinical study, which used a randomly allocated, double-blind, placebo-controlled, crossover design, examined 50 middle-aged men with mild to moderate erectile dysfunction who were treated for one month with placebo or with Pycnogenol® and L-arginine aspartate.33 Study participants recorded their sexual function/dysfunction in diaries. Investigators monitored testosterone levels and endothelial nitric oxide synthase levels along with routine clinical chemistry. Treatment with Pycnogenol® and L-arginine aspartate for one month restored erectile function to normal, and intercourse frequency doubled. Investigators found that endothelial nitric oxide synthase in spermatozoa and testosterone levels in blood increased significantly, while blood cholesterol levels and blood pressure were lowered.

The fifth clinical study used a randomly allocated, double-blind, placebo-controlled, crossover design.34 It examined 50 infertile men who were treated for one month with placebo or Pycnogenol® and L-arginine aspartate. Investigators tested semen samples at four-week intervals and found that treatment with this formula significantly increased semen volume, concentration of spermatozoa, percentage of motile spermatozoa, and percentage of spermatozoa with normal morphology compared with placebo treatment. Intake of Pycnogenol® and L-arginine aspartate for one month restored the fertility index to normal values. After treatment, the fertility index decreased again to infertile status. No adverse events were reported.

Researchers believe that improving the quality of spermatozoa from infertile status to a normal fertility index could be caused by two mechanisms: the first is that Pycnogenol® in combination with L-arginine aspartate inhibits the peroxidation of the lipid membrane of spermatozoa, thereby improving the morphology and motility of spermatozoa. The second action could be that these ingredients enhance sperm motility and function by stimulating the activity of endothelial nitric oxide synthase. Both mechanisms, perhaps acting simultaneously, have been shown to improve the quality of spermatozoa.

ERECTILE DYSFUNCTION LINKED TO ENDOTHELIAL DYSFUNCTION AND AGE
Erectile Dysfunction Linked to Endothelial Dysfunction and Age
Click Here For Larger Image

The vascular endothelium is the thin layer of cells lining the interior surface of blood vessels throughout the entire circulatory system. Endothelial cells are involved in many aspects of vascular function.

Endothelial dysfunction leads to constriction of blood vessels, inflammation, and increased tendency toward blood clotting. It is associated with the major forms ofcardiovascular disease, peripheral artery disease, diabetes, chronic renal failure, and erectile dysfunction.14,15

The aging process leads to physiological changes in male sexual activity, including erectile dysfunction (ED),reduced libido, and loss of fertility.16 A remarkable 52% of men between the ages of 40 and 70 suffer some degree of erectile dysfunction. The likelihood of erectile dysfunction increases with age, and older men are more likely to suffer from more serious erectile dysfunction.17-19

Changes in blood flow to and from the penis are thought to be the most frequent cause of male erectile dysfunction.20 Alterations of penile arterial endothelial cell function relate to arterial risk factors such as atherosclerosis and hypertension—health problems that occur more frequently as men age.

Normal endothelial function depends on nitric oxide (NO) release by endothelial cells.21 With age, arterial production and availability of NO declines.22 One reason may be that an altered form of the amino acid arginine, called ADMA(asymmetric dimethylarginine) competes with L-arginine, the precursor of nitric oxide, thus inhibiting NO production and leading to endothelial dysfunction and atherosclerotic disease.23,24 This makes adequate ingestion of arginine all the more important as we age.

Numerous conditions aside from endothelial dysfunction can also contribute to erectile dysfunction. Such conditions include: diabetes,25 prostate disease,26 prescription drug use,27 smoking,28 and psychological and physical stress.29

Icariin: Sustaining Erectile Function

Icariin is a flavonoid compound extracted from plants in the Epimedium family, which are also known as Yin Yang Huo. Chinese medicine practitioners claim that these plants produce aphrodisiac effects and help restore erectile function.

Researchers agree there is good evidence that icariin is the primary active component of Epimedium extracts. Like Viagra®, Cialis®, and Levitra®, icariin blocks the action of PDE5, the enzyme that causes erections to subside.32,39-41

Icariin enhances the production of nitric oxide in human endothelial cell culture and in animal models.42-44 Additionally, scientists have noted that icariin behaves similarly to testosterone—a significant feature, since testosterone is crucial for healthy sexual function.45 Animal research has shown that administration of Epimedium extracts improves erectile function in aged rats.46

Together, these multiple mechanisms of action suggest that icariin can help support healthy erectile function.

THE ROLE OF NITRIC OXIDE IN PENILE ERECTION AND VASCULAR HEALTH
The Role of Nitric Oxide in Penile Erection and Vascular Health

Nitric oxide (NO) is a short-lived gas that acts as a signaling molecule in the body. Among its many other functions, NO acts in concert with acetylcholine and prostaglandins as a neuro-transmitter for sexual stimulation and to dilate the small arteries in the penis that support erection.47

In addition to its role in erectile function, scientists now believe that NO deficiency may contribute to numerous degenerative diseases such as cardiovascular disease.

The arterial endothelium uses NO to signal surrounding smooth muscle cells to relax, thus dilating arteries, increasing blood flow, and maintaining normal blood pressure. NO, among its many roles, performs the following functions:

  • Relax and widen blood vessels.48
  • Facilitates the development and maintenance of erectile function.49
  • Acts as a neurotransmitter that is involved in long-term memory.50-52
  • Modulates the release of neurotransmitters.53
  • Maintain blood pressure within the normal range.54
  • Promote a healthy immune system.55
  • Play a critical role in blood clotting through its modulation of vascular tone, coagulation, fibrinolysis, and overall endothelial and vascular smooth muscle function.56

Nitric oxide can’t be taken in supplement form because it is a gas. However, nutritional ingredients such as Pycnogenol®, L-arginine aspartate, and icariin can together increase production of nitric oxide in the endothelium, and in doing so, may promote general health as well as improved erections, libido, performance, and male fertility.

Conclusion

Erectile dysfunction not only compromises intimate relationships; it can also be a harbinger of serious and potentially deadly cardiovascular disease.

Erectile Performance
Click Here For Larger Image

Scientists have found that certain nutrients not only restore erectile performance but also improve endothelial function caused by oxidative stress and diminished levels of nitric oxide. Studies and clinical trials have shown that these nutrients can potentially reduce the risk of cardiovascular disease and erectile dysfunction.

In addition to their ability to correct erectile dysfunction, these nutrients have been shown to improve libido and boost sperm viability, quantity, and motility, all of which significantly increase male fertility. Drugs prescribed to treat ED have no positive effect on fertility.

Individually and collectively, these nutrients promote systemic endothelial health and provide a consistent supply of compounds that can prevent and reverse erectile dysfunction. An estimated 330 million men worldwide will be facing vascular disease and erectile dysfunction in the near future. These clinically proven nutrients offer welcome benefits of vascular health and improved sexual function to millions of men and their partners.

For Product Link Click Here

If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.

References
1. Int J Impot Res 2008 Dec;20 Suppl 2:S9-14.2. Alderman L. For common male problem, hope beyond a pill. New York Times. August 29, 2009.3. Harefuah. 1998 Jul;135(1-2):1-2.4. Curr Med Res Opin. 2006 Nov;22(11):2111-20.5. Drug Saf. 2009;32(1):1-18.6. Drugs. 2007;67(1):75-93.

7. Can J Urol. 2006 Oct;13(5):3233-8.

8. J Laryngol Otol. 2007 Apr;121(4):395-7.

9. Biol Pharm Bull. 2008 Oct;31(10):1981-4.

10. Int J Impot Res. 2003 Apr;15(2):80-6.

11. Brain. 2003 Jan;126(Pt 1):241-7.

12. Clin Neuropharmacol. 2008 Nov;31(6):353-62.

13. Ann Pharmacother. 2005 Jul;39(7-8):1362-4.

14. Vasa. 1997 Aug;26(3):180-4.

15. Verh K Acad Geneeskd Belg. 1998;60(3):251-66.

16. World J Urol. 2002 May;20(1):28-35.

17. J Sex Res. 2002 Feb;39(1):73-8.

18. J Urol. 1994 Jan;151(1):54-61.

19. J Clin Epidemiol. 2000 Jan;53(1):71-8.

20. J Vasc Res. 2002 Jul;39(4):283-303.

21. PR Health Sci J. 1997 Jun;16(2):136-41.

22. Free Radic Biol Med. 2000 Jun 15;28(12):1806-14.

23. Diabetologia. 2002 Dec;45(12):1609-16.

24. Circulation. 1998 Nov 3;98(18):1842-7.

25. Thromb Haemost. 2006 Jan;95(1):134-41.

26. Curr Opin Urol. 2006 Jan;16(1):11-9.

27. Diabetes. 2006 Feb;55(2):530-7.

28. Clin Cardiol. 1998 May;21(5):331-4.

29. Med Sci Monit. 2001 Sep;7(5):1075-85.

30. Trends Endocrinol Metab. 2009 Aug;20(6):295-302.

31. Rohdewald P. Pycnogenol, French maritime pine bark extract. In: Coates P, ed. Encyclopedia of Dietary Supplements. New York; Marcel Dekker; 2004.

32. Urology. 2006 Dec;68(6):1350-4.

33. Int J Impot Res. 2008 Mar;20(2):173-80.

34. Phytother Res. 2009 Mar;23(3):297-302.

35. J Sex Marital Ther. 2003 May;29(3):207-13.

36. European Bulletin of Drug Research. 2005;13(1): 7–13.

37. Akush Ginekol (Sofiia). 2007;46(5):7-12.

38. European Bulletin of Drug Research. 2003;11:29-37.

39. J Huazhong Univ Sci Technolog Med Sci. 2006;26(4):460-2.

40. Asian J Androl. 2003 Mar;5(1):15-8.

41. J Nat Prod. 2008 Sep;71(9):1513-7.

42. Vascul Pharmacol. 2007 Jul;47(1):18-24.

43. Zhonghua Yi Xue Za Zhi. 2004 Jun 2;84(11):954-7.

44. Asian J Androl. 2005 Dec;7(4):381-8.

45. Asian J Androl. 2006 Sep;8(5):601-5.

46. J Ethnopharmacol. 2007 Dec 3;114(3):412-6.

47. N Engl J Med. 1992 Jan 9;326(2):90-4.

48. Curr Drug Targets Cardiovasc Haematol Disord. 2005 Feb;5(1):65-74.

49. Pharmacol Ther. 2005 May;106(2):233-66.

50. Science. 1991 Dec 6;254(5037):1503-6.

51. Annu Rev Neurosci. 1994;17:153-83.

52. Prog Brain Res. 1998;118:155-72.

53. Prog Neurobiol. 2001 May;64(1):51-68.

54. Orv Hetil. 1996 Aug 4;137(31):1699-704.

55. J Leukoc Biol. 1993 Aug;54(2):171-8.

56. Mol Med. 2002 Apr;8(4):169-78.

Posted in Erectile Dysfunction, Vascular Health | Tagged , , | Leave a comment

Book Excerpt: Wheat Belly

Wheat: The Unhealthy Whole Grain
Book Excerpt: Wheat Belly

By William Davis, MD

Flip through your parents’ or grandparents’ family albums and you’re likely to be struck by how thin everyone looks. The women probably wore size-four dresses and the men sported 32-inch waists. Overweight was something measured only by a few pounds; obesity rare. Overweight children? Almost never. Any 42-inch waists? Not here. Two-hundred-pound teenagers? Certainly not.

The women of that world didn’t exercise much at all. How many times did you see your mom put on her jogging shoes to go out for a three-mile run? Nowadays I go outdoors on any nice day and see dozens of women jogging, riding their bicycles, power walking—things we’d virtually never see 40 or 50 years ago. And yet, we’re getting fatter and fatter every year.

I am going to argue that the problem with the diet and health of most Americans is wheat—or what we are being sold that is called “wheat.”

Documented peculiar effects of wheat on humans include appetite stimulation, exposure to brain-active exorphins (the counterpart of internally derived endorphins), exaggerated blood sugar surges that trigger cycles of satiety alternating with heightened appetite, the process of glycation that underlies disease and aging, inflammatory and pH effects that erode cartilage and damage bone, and activation of disordered immune responses. A complex range of diseases results from consumption of wheat, from celiac disease—the devastating intestinal disease that develops from exposure to wheat gluten—to an assortment of neurological disorders, diabetes, heart disease, arthritis, curious rashes, and the paralyzing delusions of schizophrenia.

The sad truth is that the proliferation of wheat products in the American diet parallels the expansion of our waists. Advice to cut fat and cholesterol intake and replace the calories with whole grains that was issued by the National Heart, Lung, and Blood Institute through its National Cholesterol Education Program in 1985 coincides precisely with the start of a sharp upward climb in body weight for men and women. Ironically, 1985 also marks the year when the Centers for Disease Control and Prevention (CDC) began tracking body weight statistics, documenting the explosion in obesity and diabetes that began that very year.

So why has this seemingly benign plant that sustained generations of humans suddenly turned on us? For one thing, it is not the same grain our forebears ground into their daily bread. Wheat has changed dramatically in the past fifty years under the influence of agricultural scientists. Wheat strains have been hybridized, crossbred, and introgressed to make the wheat plant resistant to environmental conditions, such as drought, or pathogens, such as fungi. But most of all, genetic changes have been induced to increase yield per acre. Such enormous strides in yield have required drastic changes in genetic code. Such fundamental genetic changes have come at a price.

Wheat starches are the complex carbohydrates that are the darlings of dietitians. “Complex” means that the carbohydrates in wheat are composed of polymers (repeating chains) of the simple sugar, glucose. Conventional wisdom, such as that from your dietitian or the USDA, says we should all reduce our consumption of simple carbohydrates in the form of candy and soft drinks, and increase our consumption of complex carbohydrates.

Of the complex carbohydrate in wheat, 75 percent is the chain of branching glucose units, amylopectin, and 25 percent is the linear chain of glucose units, amylose. In the human gastrointestinal tract, both amylopectin and amylose are digested by the salivary and stomach enzyme amylase. Amylopectin is efficiently digested by amylase to glucose, while amylose is much less efficiently digested, some of it making its way to the colon undigested. Thus, the complex carbohydrate amylopectin is rapidly converted to glucose and absorbed into the bloodstream and, because it is most efficiently digested, is mainly responsible for wheat’s blood-sugar-increasing effect.

Wheat: Super Carbohydrate

People are usually shocked when I tell them that whole wheat bread increases blood sugar to a higher level than sucrose.1 Aside from some extra fiber, eating two slices of whole wheat bread is really little different, and often worse, than drinking a can of sugar-sweetened soda or eating a sugary candy bar.

This information is not new. A 1981 University of Toronto study launched the concept of the glycemic index, i.e., the comparative blood sugar effects of carbohydrates: the higher the blood sugar after consuming a specific food compared to glucose, the higher the glycemic index (GI). The original study showed that the GI of white bread was 69, while the GI of whole grain bread was 72 and Shredded Wheat cereal was 67, while that of sucrose (table sugar) was 59.2 Yes, the GI of whole grain bread is higher than that of sucrose. Incidentally, the GI of a Mars Bar nougat, chocolate, sugar, caramel, and all—is 68. That’s better than whole grain bread. The GI of a Snickers bar is 41—far better than whole grain bread.

This has important implications for body weight, since glucose is unavoidably accompanied by insulin, the hormone that allows entry of glucose into the cells of the body, converting the glucose to fat. The higher the blood glucose after consumption of food, the greater the insulin level, the more fat is deposited. This is why, say, eating a three-egg omelet that triggers no increase in glucose does not add to body fat, while two slices of whole wheat bread increases blood glucose to high levels, triggering insulin and growth of fat, particularly abdominal or deep visceral fat.

Trigger high blood sugars repeatedly and/or over sustained periods, and more fat accumulation results. The consequences of glucose-insulin-fat deposition are especially visible in the abdomen—resulting in, yes, wheat belly. The bigger your wheat belly, the poorer your response to insulin, since the deep visceral fat of the wheat belly is associated with poor responsiveness, or “resistance,” to insulin, demanding higher and higher insulin levels, a situation that cultivates diabetes. Moreover, the bigger the wheat belly in males, the more estrogen is produced by fat tissue. The bigger your wheat belly, the more inflammatory responses that are triggered: heart disease and cancer.

The extremes of blood sugar and insulin are responsible for growth of fat specifically in the visceral organs. Experienced over and over again, visceral fat accumulates, creating a fat liver, two fat kidneys, a fat pancreas, fat large and small intestines, as well as its familiar surface manifestation, a wheat belly. (Even your heart gets fat, but you can’t see this through the semi-rigid ribs.)

Visceral fat is different. It is uniquely capable of triggering a universe of inflammatory phenomena. Visceral fat filling and encircling the abdomen of the wheat belly sort is a unique, twenty-four-hour-a-day, seven-day-a-week metabolic factory. And what it produces is inflammatory signals and abnormal cytokines, or cell-to-cell hormone signal molecules, such as leptin, resistin, and tumor necrosis factor.3,4 The more visceral fat present, the greater the quantities of abnormal signals released into the bloodstream.

All body fat is capable of producing another cytokine, adiponectin, a protective molecule that reduces risk for heart disease, diabetes, and hypertension. However, as visceral fat increases, its capacity to produce protective adiponectin diminishes.5 The combination of lack of adiponectin along with increased leptin, tumor necrosis factor, and other inflammatory products underlies abnormal insulin responses, diabetes, hypertension, and heart disease.6 The list of other health conditions triggered by visceral fat is growing and now includes dementia, rheumatoid arthritis, and colon cancer.7 This is why waist circumference is proving to be a powerful predictor of all these conditions, as well as of mortality.8

High blood insulin provokes visceral fat accumulation, the body’s means of storing excess energy. When visceral fat accumulates, the flood of inflammatory signals it produces causes tissues such as muscle and liver to respond less to insulin. This so-called insulin resistance means that the pancreas must produce greater and greater quantities of insulin to metabolize the sugars. Eventually, a vicious circle of increased insulin resistance, increased insulin production, increased deposition of visceral fat, increased insulin resistance, etc., etc., ensues.

But you could remove wheat and an entire domino effect of changes develop: less triggering of blood sugar rises, no exorphins to drive the impulse to consume more, no initiation of the glucose-insulin cycle of appetite. And if there’s no glucose-insulin cycle, there’s little to drive appetite except genuine physiologic need for sustenance, not overindulgence. If appetite shrinks, calorie intake is reduced, visceral fat disappears, insulin resistance improves, blood sugars fall. Diabetics can become nondiabetics, prediabetics can become nonprediabetics. All the phenomena associated with poor glucose metabolism recede, including high blood pressure, inflammatory phenomena, glycation, small LDL particles, triglycerides.

If you also count the people who don’t yet meet full criteria for prediabetes but just show high after-meal blood sugars, high triglycerides, small LDL particles, and poor responsiveness to insulin (insulin resistance)—phenomena that can still lead to heart disease, cataracts, kidney disease, and eventually diabetes—you would find few people in the modern age who are not in this group, children included.

This disease is not just about being fat and having to take medications; it leads to serious complications, such as kidney failure (40 percent of all kidney failure is caused by diabetes) and limb amputation (more limb amputations are performed for diabetes than any other non traumatic disease). We’re talking real serious.

Pancreatic Assault and Battery

The cost of Americans becoming obese dwarfs the sum spent on cancer. More money will be spent on health consequences of obesity than education.

The early phase of growing visceral fat and diabetes is accompanied by a 50 percent increase in pancreatic beta cells responsible for producing insulin, a physiologic adaptation to meet the enormous demands of a body that is resistant to insulin. But beta cell adaptation has limits.

High blood sugars, such as those occurring after a nice cranberry muffin provoke the phenomenon of “glucotoxicity,” actual damage to pancreatic insulin–producing beta cells that results from high blood sugars.9

The higher the blood sugar, the more damage to beta cells. The effect is progressive and starts at a glucose level of 100 mg/dL, a value many doctors call normal. After two slices of whole wheat bread with low-fat turkey breast, a typical blood glucose would be 140 to 180 mg/dL in a nondiabetic adult, more than sufficient to do away with a few precious beta cells—which are never replaced.

Your poor, vulnerable pancreatic beta cells are also damaged by the process of lipotoxicity, loss of beta cells due to increased triglycerides and fatty acids, such as those developing from repeated carbohydrate ingestion. Recall that a diet weighted toward carbohydrates results in increased VLDL particles and triglycerides that persist in both the after-meal and between-meal periods, conditions that further exacerbate lipotoxic attrition of pancreatic beta cells.

Pancreatic injury is further worsened by inflammatory phenomena, such as oxidative injury, leptin, various interleukins, and tumor necrosis factor, all resulting from the visceral fat hotbed of inflammation, all characteristic of prediabetic and diabetic states.10

Over time and repeated sucker punches from glucotoxicity, lipotoxicity, and inflammatory destruction, beta cells wither and die, gradually reducing the number of beta cells to less than 50 percent of the normal starting number.11 That’s when diabetes is irreversibly established.

Part of the prevailing standard of care to prevent and treat diabetes, a disease caused in large part by carbohydrate consumption . . . is to advise increased consumption of carbohydrates.

Fighting Carbohydrates with Carbohydrates

Years ago, I used the ADA diet in diabetic patients. Following the carbohydrate intake advice of the ADA, I watched patients gain weight, experience deteriorating blood glucose control and increased need for medication, and develop diabetic complications such as kidney disease and neuropathy. Ignoring ADA diet advice and cutting carbohydrate intake leads to improved blood sugar control, reduced HbA1c, dramatic weight loss, and improvement in all the metabolic messiness of diabetes such as high blood pressure and triglycerides.

The ADA advises diabetics to cut fat, reduce saturated fat, and include 45 to 60 grams of carbohydrate—preferably “healthy whole grains”—in each meal, or 135 to 180 grams of carbohydrates per day, not including snacks. It is, in essence, a fat-phobic, carbohydrate-centered diet, with 55 to 65 percent of calories from carbohydrates. If I were to sum up the views of the ADA toward diet, it would be: Go ahead and eat foods that increase blood sugar, just be sure to adjust your medication to compensate.

Reduction of carbohydrates improves blood sugar behavior, reducing the diabetic tendency. If taken to extremes, it is possible to eliminate diabetes medications in as little as six months. In some instances, I believe it is safe to call that a cure, provided excess carbohydrates don’t make their way back into the diet. Let me say that again: If sufficient pancreatic beta cells remain and have not yet been utterly decimated by long-standing glucotoxicity, lipotoxicity, and inflammation, it is entirely possible for some, if not most, prediabetics and diabetics to be cured of their condition, something that virtually never happens with conventional low-fat diets such as that advocated by the American Diabetes Association.

We might gain better understanding of the aging process if we were able to observe the effects of accelerated aging. We need not look to any mouse experimental model to observe such rapid aging; we need only look at humans with diabetes. Diabetes yields a virtual proving ground for accelerated aging, with all the phenomena of aging approaching faster and occurring earlier in life—heart disease, stroke, high blood pressure, kidney disease, osteoporosis, arthritis, cancer. Specifically, diabetes research has linked high blood glucose of the sort that occurs after carbohydrate consumption with hastening your move to the wheelchair at the assisted living facility.

Advanced glycation end products, appropriately acronymed AGE, is the name given to the stuff that stiffens arteries (atherosclerosis), clouds the lenses of the eyes (cataracts), and mucks up the neuronal connections of the brain (dementia), all found in abundance in older people.12 The older we get, the more AGEs can be recovered in kidneys, eyes, liver, skin, and other organs. Although we can see evidence of some AGE effects—saggy skin and wrinkles, the milky opacity of cataracts, the gnarled hands of arthritis—none are truly quantitative. AGEs nonetheless, at least in a qualitative way, identified via biopsy as well as some aspects apparent with a simple glance, yield an index of biological decay.

AGEs are useless debris that result in tissue decay as they accumulate. They provide no useful function: AGEs cannot be burned for energy, they provide no lubricating or communicating functions, they provide no assistance to nearby enzymes or hormones. Beyond effects you can see, accumulated AGEs also mean loss of the kidneys’ ability to filter blood to remove waste and retain protein, stiffening and atherosclerotic plaque accumulation in arteries, stiffness and deterioration of cartilage in joints such as the knee and hip, and loss of functional brain cells with clumps of AGE debris taking their place.

While some AGEs enter the body directly because they are found in various foods, they are also a by-product of high blood sugar (glucose), the phenomenon that defines diabetes.

The sequence of events leading to formation of AGEs goes like this: Ingest foods that increase blood glucose. The greater availability of glucose to the body’s tissues permits the glucose molecule to react with any protein, creating a combined glucose-protein molecule. Once AGEs form, they are irreversible and cannot be undone. They also collect in chains of molecules, forming AGE polymers that are especially disruptive.13 AGEs are notorious for accumulating right where they sit, forming clumps of useless debris resistant to any of the body’s digestive or cleansing processes.

Thus, AGEs result from a domino effect set in motion anytime blood glucose increases. Anywhere that glucose goes (which is virtually everywhere in the body), AGEs will follow. The higher the blood glucose, the more AGEs will accumulate and the faster the decay of aging will proceed.

Diabetes is the real-world example that shows us what happens when blood glucose remains high, since diabetics typically have glucose values that range from 100 to 300 mg/dL all through the day as they chase their sugars with insulin or oral medications. If such repetitive high blood sugars lead to health problems, we should see such problems expressed in an exaggerated way in diabetics . . . and indeed we do. Diabetics, for instance, are two to five times more likely to have coronary artery disease and heart attacks, 44 percent will develop atherosclerosis of the carotid arteries or other arteries outside of the heart, and 20 to 25 percent will develop impaired kidney function or kidney failure an average of eleven years following diagnosis.14 In fact, high blood sugars sustained over several years virtually guarantee development of complications.

With repetitive high blood glucose levels in diabetes, you’d also expect higher blood levels of AGEs, and indeed, that is the case. Diabetics have 60 percent greater blood levels of AGEs compared to nondiabetics.15

AGEs that result from high blood sugars are responsible for most of the complications of diabetes, from neuropathy (damaged nerves leading to loss of sensation in the feet) to retinopathy (vision defects and blindness) to nephropathy (kidney disease and kidney failure). The higher the blood sugar and the longer blood sugars stay high, the more AGE products will accumulate and the more organ damage results.

AGEs form even when blood sugar is normal, though at a much lower rate compared to when blood sugar is high. AGE formation therefore characterizes normal aging of the sort that makes a sixty-year-old person look sixty years old. But the AGEs accumulated by the diabetic whose blood sugar is poorly controlled cause accelerated aging. Diabetes has therefore served as a living model for age researchers to observe the age-accelerating effects of high blood glucose. Thus, the complications of diabetes, such as atherosclerosis, kidney disease, and neuropathy, are also the diseases of aging, common in people in their sixth, seventh, and eighth decades, uncommon in younger people in their second and third decades. Diabetes therefore teaches us what happens to people when glycation occurs at a faster clip and AGEs are permitted to accumulate.

AGE formation is therefore a continuum. But while AGEs form at even normal blood glucose levels (fasting glucose 90 mg/dL or less), they form faster at higher blood sugar levels. The higher the blood glucose, the more AGEs form. There really is no level of blood glucose at which AGE formation can be expected to cease entirely.

Being nondiabetic does not mean that you will be spared such fates. AGEs accumulate in nondiabetics and wreak their age-advancing effects. All it takes is a little extra blood sugar, just a few milligrams above normal, and—voilà—you’ve got AGEs doing their dirty work and gumming up your organs. Over time, you too can develop all the conditions seen in diabetes if you have sufficient AGE accumulation.

Thus, wheat products such as your poppy seed muffin or roasted vegetable focaccia are triggers of extravagant AGE production. Wheat, because of its unique blood glucose–increasing effect, makes you age faster. Via its blood sugar/AGE-increasing effects, wheat accelerates the rate at which you develop signs of skin aging, kidney dysfunction, dementia, atherosclerosis, and arthritis.

The Great Glycation Race

There is a widely available test that, while not capable of providing an index of biological age, provides a measure of the rate of biological aging due to glycation. Knowing how fast or slow you are glycating the proteins of your body helps you know whether biological aging is proceeding faster or slower than chronological age. Thankfully, a simple blood test can be used to gauge the ongoing rate of AGE formation: hemoglobin A1c, or HbA1c. HbA1c is a common blood test that, while usually used for the purpose of diabetes control, can also serve as a simple index of glycation.

Hemoglobin is the complex protein residing within red blood cells that is responsible for their ability to carry oxygen. Like all other proteins of the body, hemoglobin is subject to glycation, i.e., modification of the hemoglobin molecule by glucose. The reaction occurs readily and, like other AGE reactions, is irreversible. The higher the blood glucose, the greater the percentage of hemoglobin that becomes glycated.

Red blood cells have an expected life span of sixty to ninety days. Measuring the percentage of hemoglobin molecules in the blood that are glycated provides an index of how high blood glucose has ventured over the preceding sixty to ninety days, a useful tool for assessing the adequacy of blood sugar control in diabetics, or to diagnose diabetes.

A slender person with a normal insulin response who consumes a limited amount of carbohydrates will have approximately 4.0 to 4.8 percent of all hemoglobin glycated (i.e., an HbA1c of 4.0 to 4.8 percent), reflecting the unavoidable low-grade, normal rate of glycation. Diabetics commonly have 8, 9, even 12 percent or more glycated hemoglobin—twice or more the normal rate. The majority of nondiabetic Americans are somewhere in between, most living in the range of 5.0 to 6.4 percent, above the perfect range but still below the “official” diabetes threshold of 6.5 percent.16,17 In fact, an incredible 70 percent of American adults have an HbA1c between 5.0 percent and 6.9 percent.18 HbA1c does not have to be 6.5 percent to generate adverse health consequences. HbA1c in the “normal” range is associated with increased risk for heart attacks, cancer, and 28 percent increased mortality for every 1 percent increase in HbA1c.19,20

That trip to the all-you-can-eat pasta bar, accompanied by a couple of slices of Italian bread and finished off with a little bread pudding, sends your blood glucose up toward 150 to 250 mg/dL for three or four hours; high glucose for a sustained period glycates hemoglobin, reflected in higher HbA1c.

HbA1c—i.e., glycated hemoglobin—therefore provides a running index of glucose control. It also reflects to what degree you are glycating body proteins beyond hemoglobin. The higher your HbA1c, the more you are also glycating the proteins in the lenses of your eyes, in kidney tissue, arteries, skin, etc.21 In effect, HbA1c provides an ongoing index of aging rate: The higher your HbA1c, the faster you are aging.

So HbA1c is much more than just a feedback tool for blood glucose control in diabetics. It also reflects the rate at which you are glycating other proteins of the body, the rate at which you are aging. Stay at 5 percent or less, and you are aging at the normal rate; over 5 percent, and time for you is moving faster than it should, taking you closer to the great nursing home in the sky.

Dr. William Davis is medical director of the online heart disease prevention and reversal program, Track Your Plaque (www.trackyourplaque.com). Join his conversations on Facebook and on his blogs, wheatbellyblog.com and trackyourplaque.com/blog.

Excerpted from Wheat Belly by William Davis, MD. Copyright© 2011 by William Davis, MD. Permission granted by Rodale, Inc., Emmaus, PA 18098.

To order a copy of Wheat Belly, call 1-800-544-4440 or visit www.LifeExtension.com Retail price $25.99 • Member price $19.49 Item #33837

References
1. Foster-Powell, Holt SHA, Brand-Miller JC. International table of glycemic index and glycemic load values: 2002. Am J Clin Nutr. 2002;76(1):5–56.

2. Jenkins DJH, Wolever TM, Taylor RH, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981 Mar;34(3):362–6.

3. Klöting N, Fasshauer M, Dietrich A, et al. Insulin sensitive obesity. Am J Physiol Endocrinol Metab. 2010 Jun 22.

4. DeMarco VG, Johnson MS, Whaley-Connell AT, Sowers JR. Cytokine abnormalities in the etiology of the cardiometabolic syndrome. Curr Hypertens Rep. 2010 Apr;12(2):93–8.

5. Matsuzawa Y. Establishment of a concept of visceral fat syndrome and discovery of adiponectin. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(2):131–41.

6. Ibid.

7. Funahashi T, Matsuzawa Y. Hypoadiponectinemia: a common basis for diseases associated with overnutrition. Curr Atheroscler Rep. 2006 Sep;8(5):433–8.

8. Deprés J, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contributions to global cardiometabolic risk. Arterioscl Thromb Vasc Biol. 2008;28:1039–49.

9. Marchetti P, Lupi R, Del Guerra S, et al. The beta-cell in human type 2 diabetes. Adv Exp Med Biol. 2010;654:501–14.

10. Ibid.

11. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007 Apr;28(2):187–218.

12. Bengmark S. Advanced glycation and lipoxidation end products—amplifiers of inflammation: The role of food. J Parent Enter Nutr. 2007 Sept-Oct;31(5):430–40.

13. Uribarri J, Cai W, Peppa M, et al. Circulating glycotoxins and dietary advanced glycation endproducts: Two links to inf lammatory response, oxidative stress, and aging. J Gerontol. 2007 Apr;62A:427–33.

14. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999 Jan;22(1):99–111.

15. Kilhovd BK, Giardino I, Torjesen PA, et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism. 1003;52:163–7.

16. Sarwar N, Aspelund T, Eiriksdottir G, et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLos Med. 2010 May 25;7(5):e1000278.

17. International Expert Committee. International Expert Committee report on the role of the HbA1c assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327–44.

18. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). Brit Med J. 2001 Jan 6;322(7277):15–8.

19. Gerstein HC, Swedberg K, Carlsson J, et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med. 2008 Aug 11;168(15):1699–704.

20. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001 Jan 6;322(7277):15-8.

21. Swami-Mruthinti S, Shaw SM, Zhao HR, et al. Evidence of a glycemic threshold for the development of cataracts in diabetic rats. Curr Eye Res. 1999 Jun;18(6):423–9.

Posted in Book Review, Gluten Free, Weight Control | Leave a comment

Life Extension picks up weight-management supp from InterHealths

Source:InterHealth Nutraceuticals, Inc., NPI Center

InterHealth Nutraceuticals’ latest weight management ingredient, Merastin is featured in a new product from Life Extension, a leader in superior quality, research-backed dietary supplements.

InterHealth Nutraceuticals’ latest weight management ingredient, Merastin™, is featured in a new product from Life Extension, a leader in superior quality, research-backed dietary supplements. Life Extension introduced Anti-Adipocyte Formula with AdipoStat into various channels, including direct-to-consumer, health food retailers, healthcare practitioners, and independent pharmacies.

Preliminary results from two randomized, double-blind, placebo-controlled clinical studies demonstrate the safety and efficacy of Merastin™. Research shows that Merastin™ works in just two weeks to significantly reduce body weight as well as reduce hip and waist circumference. Preliminary results from the second clinical study demonstrating significant average weight loss of over 4 pounds at two weeks and over 11 pounds at eight weeks were presented at the 2011 Experimental Biology meeting in April in Washington, D.C.

Life Extension’s Anti-Adipocyte Formula modulates the activity of biomolecular pathways involved in fat cell formation and breakdown. This benefit is due to Merastin™’s blend of two proprietary plant extracts, Sphaeranthus indicus flower heads and Garcinia mangostana fruit rind. “Based on an exhaustive review of the science and clinical studies behind Merastin™, the choice for Life Extension was clear,” stated Steven V. Joyal, MD, vice president of Scientific Affairs for Life Extension. “Merastin™, in combination with a reduced calorie diet and exercise, provides natural support for healthy weight management.” Expressing his excitement over having Merastin™ represented by a well known and well respected company as Life Extension, Paul Dijkstra, InterHealth’s CEO stated, “Given the brand recognition and consumer trust and dedication to Life Extension’s research and products, Anti-Adipocyte Formula is certain to attract consumer attention.”

With weight management issues continuing to plague the country, Life Extension aims to educate consumers about how Anti-Adipocyte Formula can help with their weight management efforts. A feature article that appeared in the July 2011 issue of Life ExtensionMagazine®, entitled “Shed Pounds by Inhibiting Cellular Fat Storage<http://www.lef.org/magazine/mag2011/jul2011_Shed-Pounds-by-Inhibiting-Cellular-Fat-Storage_01.htm>,” helps consumers gain understanding of what causes people to accumulate so many fat pounds as they age and how they can help to address the issue. “The industry needs to increase consumer awareness of how important managing weight truly is and how maintaining a healthy weight is closely related to healthy aging,” added Dijkstra.

About InterHealth Nutraceuticals, Inc.

InterHealth Nutraceuticals researches, develops, markets and distributes specialty nutritional ingredients, which are sold worldwide to manufacturers of dietary supplements and nutraceutical food and beverage products. The company’s products include Merastin™ for addressing fat storage and facilitating fat breakdown for weight management; Super CitriMax®, a satiety ingredient for weight management; UC-II®, a natural ingredient for joint health; and Zychrome™, next generation chromium that addresses insulin function. In addition, InterHealth offers ChromeMate®, LOWAT™, Aller-7®, OptiBerry®, L-OptiZinc®, Protykin® and ZMA®. For more information about InterHealth and its products, call 1-800-783-4636 or 1-707-751-2800 (outside U.S.) or visit www.interhealthusa.com.

About Life Extension

For 30 years, Life Extension® has been a pioneer in funding and reporting on the latest anti-aging research and integrative health therapies while offering superior quality dietary supplements to consumers. A trailblazer in the $26 billion U.S. dietary supplements industry, Life Extension is composed of the non-profit Life Extension Foundation®, the Life Extension Foundation Buyer’s Club and Life Extension Pharmacy®. For more information, visitwww.lef.org.

Posted in Weight Control | Tagged | Leave a comment

Does coconut water pack the nutrient punch that it promises?

Source: by Kelsey Blackwell in New Hope 360 Blog
A recent study calls into question the hydration capabilities of two coconut beverages, but can the information be trusted?
After a particularly vigorous workout session, I’ll occasionally treat myself to one of the bevy of coconut waters on the market. Naturally high in hydration-supporting electrolytes and potassium, coconut water is like nature’s Gatorade sans the artificial colors and sugar—at least, that’s what I’ve been happy to believe. A recent report from ConsumerLab.com potentially bursts my electrolyte bubble.
The independent testing company investigated three popular brands: O.N.E. Coconut Water, Zico Natural Pure Premium Coconut Water and Vita Coca 100% Pure Coconut Water. While all contained significant amounts of potassium, two of the products had significantly less sodium than was claimed—18 percent and 59 percent of the listed amounts. Sodium, of course, is key for hydration as any sweat-drenched gym rat can attest. Two of the beverages also fell short on magnesium—77 percent and 64 percent of the listed amounts.
While this information is a bit of a blow, I’m not kicking coconut water from my post-workout regimen just yet. ConsumerLab.com is a noted controversial figure within the natural products industry. The Westchester, New York-based company relies on third-party labs for data, and testing methods can be dubious. Additionally, the agency is accused of designing studies to encourage negative results. Companies can pay to keep information from being published.
I’d be interested to hear what another research body has to say on the subject and would welcome comments from those coconut beverages that were called out. After bringing up the study at a recent editorial meeting, this is exactly what my colleagues and I plan to do. Expect more coverage on the coconut beverage category including an in-depth look at nutrition claims on NewHope360 later this month.

Posted in Uncategorized | Tagged , | Leave a comment

Study finds soy may not provide relief during menopause

Taking soy supplements may not help women ease their menopause symptoms or prevent the bone changes that start at that time of life, suggests a new study from Florida.

Taking soy supplements may not help women ease their menopause symptoms or prevent the bone changes that start at that time of life, suggests a new study from Florida.

Women who took the supplements every day for two years didn’t have any improvement in their symptoms compared with those who took a soy-free placebo pill—and they suffered more hot flashes by the end of the study.
Researchers also didn’t see any changes in their bone mineral density compared to women taking placebos. Low bone mineral density puts women at higher risk of osteoporosis and broken bones.
Women seeking relief from menopause symptoms have been without a clear go-to treatment since the Women’s Health Initiative (WHI) study of hormone therapy reported heart and cancer risks with estrogen and progestin use.
Previous studies have shown that soy supplements don’t have those same added risks. But the studies have also found mixed results on soy’s ability to slow bone weakening and ease hot flashes and other menopause symptoms.
“What prompted us to do this study was in the wake of WHI when many of our patients stopped using hormone therapy,” said Dr. Silvina Levis, the study’s lead author from the Miller School of Medicine, University of Miami.
“Many of them had just gone to a health food store and started on soy supplements,” she told. “The study was started to try to answer a simple question: will these soy isoflavone tablets help women with the issues they were concerned with?”
Levis and her team randomly split 248 women who had recently hit menopause into two groups. For two years, half of the women took 200 milligrams of soy isoflavones every day—about twice the amount that would be in a soy-rich diet. The other half took placebo pills. None of them knew whether they were getting the real or sham treatment.
Most of the participants were Hispanic, and 182 completed the study.
At their two-year visit, women in both groups had lost the same amount of bone density in their spine and hip since starting the study. They also reported a similar number of menopause symptoms, except more women in the soy group said they had hot flashes—48 percent of them, compared to 32 percent in the placebo group.
Women taking the daily soy supplements also reported some of the stomach and digestion problems, such as constipation, that have been linked to soy before, Levis said. But there were no serious side effects related to the supplements, the authors report in Archives of Internal Medicine.
The soy tablets can be bought for about 25 to 50 cents per day.
“When we started the study we wanted this to work, because it would provide an easy and healthy way to help women in the initial stages of menopause,” Levis said.
However, “we didn’t see any protection from bone loss or any relief from menopause symptoms.” After this, she added, “maybe women will reconsider” taking soy tablets during menopause.
William Wong, a nutritionist at Baylor College of Medicine in Houston who didn’t participate in the new study, agreed. “The scientific evidence is telling them that they might not receive any benefit” from extra soy, he told Reuters Health.
Wong, whose research has also shown a lack of effect of soy during menopause, said that doesn’t mean soy couldn’t have health benefits over a longer period of time—such as if girls started getting more of it during puberty.
Medications including certain anti-depressants may provide relief for menopause symptoms in some women, Levis said. For bone health, Wong recommended regular physical activity, combined with calcium and vitamin D supplements.

Source: Archives of Internal Medicine, NPI Center

Posted in Menopause, Soy | Tagged , | Leave a comment

Vitamin D lack and pneumonia up death risk

United Press International

05-11-11

Adult patients lacking in vitamin D were more likely than others to die soon after being hospitalized with pneumonia, researchers in New Zealand say.

Researchers at Waikato Hospital, the University of Waikato and the University of Otago measured vitamin D in the blood samples of 112 adult patients admitted with community-acquired pneumonia during the winter at the only acute-care hospital in Hamilton, New Zealand.

The researchers found vitamin D deficiency was associated with higher mortality within the first 30 days after hospital admission for pneumonia. The association between vitamin D deficiency was not explained by patient age, sex, co-morbidities, the severity of the systemic inflammatory response or other known prognostic factors.

The study authors say “improved understanding of vitamin D and its role in immunity may lead to better ways to prevent and/or treat pneumonia.”

“We now need to investigate whether vitamin D supplements could be a useful addition to pneumonia treatment and whether using supplements could help to prevent or reduce the severity of pneumonia among high-risk populations,” the study authors said in a statement.

The study was published in the journal Respirology.

Copyright United Press International 2011

Posted in Vitamin D | Tagged , | Leave a comment

Astaxanthin the Neroprotector

Substantial evidence shows most diseases associated with the brain are the result of oxidation and/or inflammation. Free radicals and singlet oxygen wreak havoc over time in the head, and the consequences, if left unchecked, manifest in such horrible conditions as:

  • Alzheimer’s disease
  • Parkinson’s disease
  • Huntington’s disease
  • Amyotrophic lateral sclerosis (Lou Gehrig’s disease)
  • Senility
  • Injuries resulting from trauma
  • Inflammatory injuries
  • Other forms of age-related dementia

Antioxidants that can cross the blood-brain barrier are essential for people as they get older to protect the brain and central nervous system. Scientists believe something may cause people’s internal antioxidant defense system to malfunction or wear out as they age.  Our bodies may lose the ability to produce high levels of the antioxidants that are normally produced internally such as superoxide dismutase (SOD), catalase and glutathione peroxidase. Also, our bodies are now subjected to unprecedented levels of oxidation caused by environmental factors such as pollution, containments, processed food and the high levels of stress in modern life. All of these lead to an assault on vital organs as we age, particularly our brains and eyes.

Recent research has validated astaxanthin’s ability to protect our central nervous system. A great deal of this research has been centered on the neuroprotective benefits of astaxanthin. Two human clinical trials were done in Japan in the last two years in this area. The first study took 10 elderly subjects with age-related forgetfulness and administered 12 mg of astaxanthin each day for 12 weeks.1 The researchers found efficacy for age-related decline in cognitive and psychomotor function.

The second study was randomized, double blind and placebo-controlled; a state-of-the-art study in human volunteers.2 After 12 weeks at either 6 mg or 12 mg of daily astaxanthin, subjects were found to have decreased levels of phospholipid hydroperoxides (which accumulate in people suffering from dementia), as well as improved erythrocyte antioxidant status. The researchers concluded astaxanthin supplementation may contribute to the prevention of dementia in humans as they age.
Several other studies in the last two years have shown evidence that astaxanthin may be the best supplement for brain health:

  • Human brain cells were subjected to an oxidative stress-induced neuronal cell damage system at Nagoya University in Japan.3 Significant protection was found in cells pre-treated with astaxanthin. Additionally, pre-treatment with astaxanthin inhibited the generation of reactive oxygen species. The authors concluded, “The neuroprotective effect of astaxanthin is suggested to be dependent upon its antioxidant potential and mitochondria protection; therefore, it is strongly suggested that treatment with astaxanthin may be effective for oxidative stress-associated neurodegeneration and a potential candidate for natural brain food.”
  • A different set of researchers at University of Pittsburgh’s medical school also found astaxanthin to have neuroprotective effects; they too attributed this to its potent antioxidant activity.4
  • Researchers at a biotechnology university in Taiwan concluded astaxanthin could be used as a potent neuron protectant and as a therapy for early stages of Alzheimer’s disease.5
  • Astaxanthin can protect against damage from ischemia, the condition where there is a deficient supply of blood to the brain as a result of an obstruction of the arteries, which results in stroke, brain cell death and impaired brain function.6 The researchers attributed astaxanthin’s benefits to its intense antioxidant activity.
  • Another study found that pretreatment with astaxanthin five hours and again one hour before ischemia provided protection against brain damage.7
  • Astaxanthin was found to be a potent agent against neurodegenerative disorders.8
  • Brain cell death was reduced by astaxanthin.9
  • Lastly, astaxanthin displayed an ability to improve the profileration of neural stem cells.10

The flurry of activity in 2009 and 2010 was not the first research on astaxanthin’s benefits for the brain; a series of tests on rodents prior to this at the International Research Center for Traditional Medicine in Japan showed astaxanthin’s potential as a supplement for the brain.11 In the first experiment, blood pressure was reduced by the introduction of astaxanthin to hypertensive rats. Blood pressure is a causative factor for many diseases including some associated with the eyes and brain. The researchers went on to examine the effects of astaxanthin on stroke-prone rats. They found after five weeks of continuous supplementation, the incidence of stroke was delayed in the treated group. Next, they established a possible mechanism for these results in-vitro, which they believed to be nitric oxide suppression.

The same study went on to demonstrate a neuroprotective effect on ischemic mice. In the case of these mice, ischemia was induced by blocking the carotid artery. In humans, this condition can be caused by plaque buildup, which can block the flow of blood through the carotid artery in the neck, the primary source of blood to the brain. This build up of plaque can lead to many different types of dementia.

 

The ischemic mice were fed astaxanthin only once—just one hour before the ischemia was induced. Remarkable results were seen in the treated group—the mice performed better in a maze designed as a learning performance test. “The present results suggest that astaxanthin can attenuate the development of hypertension and may help to protect the brain from stroke and ischemic insults…In addition, astaxanthin showed neuroprotective effects at relatively high doses by preventing the ischemia-induced impairment of spatial memory in mice. This effect is suggested to be due to the significant antioxidant property of astaxanthin on ischemia-induced free radicals and their consequent pathological cerebral and neural effects. The current result indicates that astaxanthin may have beneficial effects in improving memory in vascular dementia.” It appears that astaxanthin actually made these mice with restricted blood flow to their brains smarter by improving their memory.

A similar study had been done previously and was published in Carotenoid Science.12 This study also demonstrated that astaxanthin could prevent brain damage due to ischemia. A company in Japan did some further work in this area in a rat model.13 The company fed rats astaxanthin twice: Twenty-four hours before and again one hour before inducing ischemia by occluding the rats’ middle arteries. The blood flow stoppage duration was one hour, at which point blood flow to the brain was permitted to resume. The rats were given one more dose of astaxanthin after blood flow restarted, and then two hours later, the rats were sacrificed and their brains were removed. The brains were compared to rats from a control group fed olive oil, and it was found that the rats fed astaxanthin had 40-percent less brain damage than the control group.  
Strong evidence shows astaxanthin holds great promise for those wishing to prevent cognitive diseases and maintain general brain health. In particular, daily supplementation with astaxanthin may have tremendous benefits for those wishing to protect there brains as they age. The implications of the studies cited above are extremely exciting, as our aging population sees growing numbers of Alzheimer’s patients, stroke sufferers and people afflicted by dementia caused by other factors.

Bob Capelli, vice president of sales and marketing for Cyanotech Corp., graduated from Rutgers University with a degree in liberal arts. He spent four years traveling and working in developing countries in Asia and Latin America while he was in his 20s. Upon returning to the United States, Capelli began working in the natural supplement and herb industry, where he has remained for the last 19 years. 
Gerald Cysewski has more than 30 years experience in microalgae research and commercial production of microalgae products. Cysewski co-founded Cyanotech in 1983 in Washington. As the company’s scientific director, he launched the commercial production of microalgae in the Kona coast of Hawaii. Cysewski holds a bachelor’s of science in chemical engineering from the University of Washington and a doctorate in chemical engineering from the University of California at Berkeley.


References:
1.       Satoh, A., Tsuji, S., Okada, Y., Murakmi, N., Urami, M., Nakagawa, K., Ishikura, M., Katagiri, M., Koga, Y., Shirasawa, T. (2009) “Preliminary Clinical Evaluation of Toxicity and Efficacy of a New Astaxanthin-rich Haematococcus pluvialis Extract.” Journal of Clinical Biochemistry and Nutrition, 2009:44(3):280-4.
2.       Nakagawa, K., Kiko, T., Miyazawa, T., Carpentero Burdeos, G., Kimura, F., Satoh, A., Miyazawa, T. (2011) “Antioxidant effect of Astaxanthin on phospholipid peroxidation in human erythrocytes.” British Journal of Nutrition, 2011: Jan 31:1-9.
3.       Liu, X., Osawa T. (2009) “Astaxanthin Protects Neuronal Cells against Oxidative Damage and is a Potent Candidate for Brain Food.” Forum Nutr. Basel, Karger, 2009, vol 61, pp 129-135.
4.       Lee, DH., Lee, YJ., Kwon, KH. (2010). “Neuroprotective Effects of Astaxanthin in Oxygen-Glucose Deprivation in SH-SY5Y Cells and Global Cerebral Ischemia in Rat.” Journal of Clinical Biochemistry and Nutrition 2010:47(2):121-9.
5.       Chang, CH., Chen, CY., Chiou, JY., Peng, RY., Peng, CH. (2010). “Astaxanthin secured apoptic death of PC12 cells induced by beta-amyloid peptide 25-35: its molecular action targets.” Journal of Medicinal Food 2010:13(3):548-56.
6.       Curek, GD., Cort, A., Yucel, G., Demir, N., Ozturk, S., Elpek, GO., Savas, B., Aslan, M. (2010). “Effect of Astaxanthin on hepatocellular injury following ischemia/reperfusion.” Journal of Toxicology 2010:267(1-3):147-53.
7.       Lu, YP., Liu, SY., Sun, H., Wu, XM., Li, JJ., Zhu, L. (2010). “Neuroprotective Effect of Astaxanthin on H(2)O(2)-Induced Neurotoxicity In-Vitro and on Focal Cerebral Ischemia In-Vivo.” Brain Research 2010: Sept. 21.
8.       Chan, KC., Mong, MC., Yin, MC. (2009). “Antioxidant and anti-inflammatory neuroprotective effects of astaxanthin and canthaxanthin in nerve growth factor differentiated PC12 cells.” Journal of Food Science 2009:74(7):H225-31.
9.       Wang, HQ., Sun, XB., Xu, YX., Zhao, H., Zhu, QY., Zhu, CQ. (2010). “Astaxanthin upregulates heme oxygenase-1 expression through ERK1/2 pathway and its protective effect against beta-amyloid-induced cytotoxicity in SH-SY5Y cells.” Brain Research 2010:Sept 7.
10.   Kim, JH., Nam, SW., Kim, BW., Kim, WJ., Choi, YH. (2010). “Astaxanthin Imrpoves the Proliferative Capacity as well as the Oxteogenic and Adipogenic Differentiation Potential in Neural Stem Cells.” Food Chemistry and Toxicology 2010:48(6):1741-5.
11.   Hussein, G., Nakamura, M., Zhao, Q., Iguchi, T., Goto, H., Sankawa, U., Watanabe, H. (2005). “Antihypertensive and neuroprotective effects of astaxanthin in experimental animals.” Biological and Pharmaceutical Bulletin. 28(1):47-52.
12.   Kudo, Y., Nakajima, R., Matsumoto, N. (2002). “Effects of astaxanthin on brain damages due to ischemia” Carotenoid Science. 5,25.
13.   Oryza Oil & Fat Chemical Company. (2006). “Natural Antioxidant for Neuro-protection, Vision Enhancement & Skin Rejuvenation.” September 7, 2006.

Posted in Astaxanthin, Brain Health | Tagged , , , , | Leave a comment

Healthy nails are within your reach

By Michelle Healy, USA TODAY
Source: USA TODAY

Green nail polish may be hot this summer, but “it makes me think about nail infections,” says dermatologist Cynthia Bailey.

Black or green discoloration is usually a sign of a bacterial infection, says Bailey, of Sebastopol, Calif.

Fungus, yeast and discolorations are some of the conditions that can send us seeking medical attention.

And for good reason. “Changes in the nail can signal problems with your overall health,” says Joshua Zeichner, director of Cosmetic and Clinical Research at Mount Sinai Hospital’s Department of Dermatology in New York. Liver disease, kidney disease, medication side effects, even certain cancers can cause changes in the nails, he says.

Serious medical conditions aside, even routine dish-washing or getting a manicure can be hard on nails. But we can lessen the damage, experts say:

Protect cuticles. The strip of hardened skin at the base and sides prevents microbes from infecting your nails. Damage it and you risk the nasty infection paronychia, Bailey says. It’s OK to push cuticles back gently, but don’t cut them, Zeichner says. “If you get a hangnail, cut it cleanly with a cuticle scissor, but don’t pick at it. That can lead to infection.”

Get wet. Clipping and filing dry nails only makes splitting worse, Bailey says. After showering or soaking nails, “towel off the water and use sharp clippers, followed by gently buffing the edges.” Nails should be cut straight across to prevent edges from becoming ingrown, a condition that can lead to painful infection, Zeichner says.

Baby your brittle nails. Age and harsh products “reduce the natural oils that act as a glue to hold the nail layers together,” Bailey says. To counter the loss, apply cream, oil or ointment to the hands and nails several times a day, she adds. “Regularly applying a thick cream like Bag Balm, for example, at bedtime for several months makes a big difference.”

Limit the use of nail polish removers, including acetone-free varieties, which are very hard on fragile nails, she says.

And your mother was wise when she put on rubber gloves to wash the dishes, Zeichner says: “Excess exposure to water, especially warm water, can dehydrate the skin and nails.”

Be patient. Fingernails grow about one-tenth of an inch a month, the American Academy of Dermatology says. Gelatin capsules won’t speed it up, Bailey says, but vitamin supplements containing biotin “may help weak or fragile nails, as does a balanced diet.”

Practice salon smarts. Some people are allergic to chemicals used in acrylic nails and can develop severe rashes that can spread, Bailey says. Applying acrylic nails also “creates many nooks and crannies for organisms to live, which can result in fungal, bacterial and yeast infections,” she says.

Sanitation “is always in the forefront of the nail industry,” says Sree Roy, managing editor of Nails Magazine, which covers salons. Though state health departments regulate salon sanitation, clients should ask about how a salon handles sanitation and disinfection, look for its policy statement on the premises or on its website, and look for salons that highlight good sanitation.

Opt for non-toxic polishes. An increasing number of nail polishes have been reformulated to remove potentially carcinogenic ingredients dibutyl phthalate (DBP), formaldehyde and toluene. “But even within the same brand, some may still contain some of these ingredients, so it is important to check the individual color,” Zeichner says. If the label isn’t clear, he recommends checking the Environmental Working Group’s Skin Deep Cosmetic Database (ewg.org/skindeep) for personal-care product safety information.

(c) Copyright 2011 USA TODAY, a division of Gannett Co. Inc.

Copyright USA TODAY 2011

Posted in Healthy Nails, Uncategorized | Tagged | Leave a comment

Lupeol a candidate for prostate cancer research

Institute makes stride in cancer research

Source: Knight Ridder/Tribune Business News

July 27–Lupeol, a chemical constituent found in fruits, vegetables and medicinal plants, shows strong potential for being tested in clinical trials to treat prostate cancer, according to a study led by researchers at The Hormel Institute, University of Minnesota-Mayo Clinic.

Dr. Mohammad Saleem, head of the Molecular Chemoprevention and Therapeutics section at The Hormel Institute, and his team recently published a study titled, “Lupeol, a Novel Androgen Receptor Inhibitor: Implications in Prostate Cancer Therapy,” in Clinical Cancer Research, a journal of the American Association for Cancer Research. The journal focuses on innovative clinical and translational cancer research studies that bridge the laboratory and the clinic.

“We suggest that lupeol alone or added to a drug has enormous translational potential to be tested in humans for prostate cancer treatment,” Saleem said.

Dr. R. Jeffrey Karnes of Mayo Clinic’s Department of Urology, is one of the co-authors of the study, which recently has been featured in the The New York Times, The Wall Street Journal and other national media.

According to the American Cancer Society, 217,730 men were diagnosed with prostate cancer and another 32,050 prostate-cancer patients died during 2010 in the United States.

Despite initial efficacy of androgen-deprivation therapy, prostate cancer progresses within a few years from androgen-dependent prostate cancer to castration-resistant prostate cancer in most of the patients, the study says. Accumulating evidence suggests androgen receptor is a critical player in the development of early androgen-dependent prostate cancer as well as late-stage castration-resistant prostate cancer.

There is great interest in identifying agents that are effective inhibitors of androgen-receptor signaling, can act independently of hormonal status and possibly reduce the rates of occurrence and mortality of prostate-cancer patients.

Agents that inhibit androgen-receptor signaling in both ADPC and CRPC conditions could be extremely useful for treating patients with prostate cancer, and lupeol qualifies as such an agent, Saleem says.

“This study shows that lupeol, by adopting several approaches, inhibits androgen receptor signaling in prostate cancer of both androgen-dependent and castration-resistant prostate cancer,” Saleem said.

Lupeol — a nontoxic, diet-derived agent found in foods such as strawberries, olives, grapes, apples and cucumbers — possesses strong antioxidant, anti-inflammatory, antiarthritic, antimutagenic and antimalarial activity in laboratory studies.

This research is clinically relevant, Saleem says, because it shows lupeol sensitizes prostate-cancer cells, which generally do not respond to therapy, to become responsive to clinical therapeutic agents and reduces PSA, the clinical biomarker for prostate cancer diagnosis and prognosis.

The Hormel Institute is a world-renowned medical research center in Austin, Minnesota, specializing in research leading to cancer prevention and control, including by studying how plant-based food chemicals behave inside the body and how they might be used to fight cancer.

Established in 1942, The Hormel Institute is a research unit of the University of Minnesota and collaborative cancer research partner with Mayo Clinic.

—–

To see more of the Austin Daily Herald or to subscribe to the newspaper, go to http://www.austindailyherald.com/.

Copyright (c) 2011, Austin Daily Herald, Minn.

Distributed by McClatchy-Tribune Information Services.

For more information about the content services offered by McClatchy-Tribune Information Services (MCT), visit www.mctinfoservices.com.

Posted in Cancer Research, Prostate Cancer | Tagged , | Leave a comment

Drug improves brain function in condition that leads to Alzheimer’s

NewsRx.com

07-28-11

An existing anti-seizure drug improves memory and brain function in adults with a form of cognitive impairment that often leads to full-blown Alzheimer’s disease, a Johns Hopkins University study has found (see also Alzheimer Disease).

The findings raise the possibility that doctors will someday be able to use the drug, levetiracetam, already approved for use in epilepsy patients, to slow the abnormal loss of brain function in some aging patients before their condition becomes Alzheimer’s. The researchers emphasize, however, that more studies are necessary before any such recommendation can be made to doctors and patients.

The effects seen in the study “could be like taking your foot off the accelerator or tapping the brakes, and possibly could slow the progression on that path [to Alzheimer's],” said principal investigator and neuroscientist Michela Gallagher. “We need further clinical studies with longer exposure to the drug to, first of all, make sure with rigorous evaluation that the drug is effective in the longer term and, equally important, that it does no harm.”

The new study, presented July 20 at the International Congress on Alzheimer’s Disease in Paris, also shows that excess brain activity in patients with a condition known as amnestic mild cognitive impairment, or aMCI, contributes to brain dysfunction that underlies memory loss. Previously, it had been thought that this hyperactivity was the brain’s attempt to “make up” for weakness in its ability to form new memories.

The clinical study, funded by the National Institutes of Health, tested 34 participants, some healthy older adults and others with aMCI, meaning that they had memory difficulties greater than would be expected at their age. Each person participated in a sequence of two treatment phases lasting two weeks each. Patients received a low dose of levetiracetam during one phase and a placebo during the other.

After each treatment phase, the researchers evaluated subjects’ memory and conducted functional magnetic resonance imaging of their brains. These scans were used to map brain activity during performance of a memory task, allowing the researchers to compare each individual’s status both on and off the drug. Compared to the normal participants, subjects with amnestic MCI who took the placebo had excess activity in the hippocampus, a part of the brain essential for memory. But when they had been taking levetiracetam for two weeks, the excess activity was reduced to the same level as that of the control subjects; memory performance in the task they performed also was improved to the level of the controls.

The findings have possible implications for the progression to Alzheimer’s disease. Studies showing excess activity in the hippocampus in patients with aMCI have found that if these patients are followed for a number of years, those with the greatest excess activation have the greatest further drop in memory and are more likely to receive a diagnosis of Alzheimer’s over the next four to six years.

Other recent research provides a clue as to why this might be the case, says Gallagher, the Krieger-Eisenhower Professor of Psychological and Brain Sciences in Johns Hopkins’ Krieger School of Arts and Sciences.

“Because some of the physiology that creates Alzheimer’s disease in the brain is driven by greater brain activity, this excess activity might be like having your foot on the accelerator if you are on the path to Alzheimer’s,” Gallagher said. “So the next step in this line of research will be to test that idea to see whether reducing excess activity might actually slow progression to Alzheimer’s for patients with aMCI.”

Between 8 and 15 percent of patients with aMCI progress to an Alzheimer’s diagnosis every year, making aMCI a stage of transition between normal aging and neurodegenerative disease. At present there is no effective treatment to modify this progression before irreversible damage has occurred in the brain. It would be a significant breakthrough to slow the progression of Alzheimer’s, a disease that is expected to affect as many as 16 million Americans by 2050.

Levetiracetam, the drug used in the study, is an anticonvulsant that decreases abnormally high activity in the brain. It is combined with other drugs to treat certain types of epileptic seizures.

The team that conducted the Johns Hopkins study included Marilyn Albert and Gregory Krauss, both professors of neurology at the Johns Hopkins University School of Medicine, and Arnold Bakker, a graduate student in Gallagher’s laboratory, who presented the findings at the Alzheimer’s conference.

Gallagher is the founder of, and a member of the scientific board of, AgeneBio, a biotechnology company focused on developing treatments for diseases that have an impact on memory, such as amnestic mild cognitive impairment and Alzheimer’s disease. The company is headquartered in Indianapolis. Gallagher owns AgeneBio stock, which is subject to certain restrictions under Johns Hopkins policy. She is entitled to shares of any royalties received by the university on sales of products related to her inventorship of intellectual property. The terms of these arrangements are managed by the university in accordance with its conflict-of-interest policies.

Keywords: Dementia, Tauopathies, Brain Diseases, Alzheimer Disease, Central Nervous System Diseases.

This article was prepared by Biotech Week editors from staff and other reports. Copyright 2011, Biotech Week via NewsRx.com.

To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .

2007 NewsRx.com. All Rights Reserved.Copyright 2011, Biotech Week via NewsRx.com

Posted in Alzheimer's Disease, Brain Health | Leave a comment